The retrospective analysis of patients with uterine sarcomas: A single-center experience

Basit Öğe Kaydı
dc.contributor.authorTerek, Mustafa Cosan
dc.contributor.authorAkman, Levent
dc.contributor.authorHursitoglu, Behiye Seda
dc.contributor.authorSanli, Ulus Ali
dc.contributor.authorOzsaran, Zeynep
dc.contributor.authorTekindal, Mustafa Agah
dc.contributor.authorDikmen, Yilmaz
dc.contributor.authorZekioglu, Osman
dc.contributor.authorOzsaran, Ahmet Aydin
dc.date.accessioned2019-10-27T22:58:05Z
dc.date.available2019-10-27T22:58:05Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Uterine sarcomas are rare, malignant, gynecological tumors and show diverse histopathological features. Therefore, there is no consensus on risk factors for poor outcome and optimal treatment. The aim of this retrospective analysis is to report the clinical outcome of patients with uterine sarcoma treated at a single center. Materials and Methods: The data was obtained regarding the patient's demographic characteristics, pathological results, treatments given, survival, and complications of all uterine sarcoma patients treated in a single center between the years 2000 and 2012. The 80-month overall survival (OS) was determined with respect to prognostic factors including age, stage of disease, histopathological type, and adjuvant treatment. Results: A total of 57 case records are retrieved for this retrospective analysis. The mean age of the patients is 62.5 +/- 11.2 years. International Federation of Gynecology and Obstetrics (FIGO) stage distribution is stage I: 29; stage II: 13; stage III: 9; stage IV: 6. Fifty-seven patients underwent surgery, 33 received postoperative radiotherapy (PORT), and 32 received chemotherapy. Median follow-up period was 25 months (range 2-85 months). The 80-month OS for the entire group of patients was 36.7%. The significant prognostic factors for survival are age under 50 years, stage of disease, and adjuvant chemotherapy. Conclusion: Although limited by small sample size and retrospective nature, age under 50 years, stage of disease, and adjuvant chemotherapy are significant prognostic factors for survival for uterine sarcomas.en_US
dc.identifier.doi10.4103/0973-1482.148698en_US
dc.identifier.endpage313en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue1en_US
dc.identifier.pmid27072256en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage309en_US
dc.identifier.urihttps://doi.org/10.4103/0973-1482.148698
dc.identifier.urihttps://hdl.handle.net/11454/51433
dc.identifier.volume12en_US
dc.identifier.wosWOS:000378176100056en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal of Cancer Research and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapyen_US
dc.subjectradiotherapyen_US
dc.subjectsurvivalen_US
dc.subjectuterine sarcomaen_US
dc.titleThe retrospective analysis of patients with uterine sarcomas: A single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu